Evidence map›Paper›PMID 26090599›Full record

ArticleMonoclonal antibodies in immunodiagnosis and immunotherapy2015

SPLUNC1 Is a Significant Marker in Pleural Effusion from Lung Cancer Compared to Tuberculosis.

Jun L Xue, Ling Yi, Zhou H Yan, Xin Li, Xiao J Wang, Pang J Wei, Jiao E Zeng, Yan L Zhao, Hong T Zhang

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Monoclonal antibodies in immunodiagnosis and immunotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Crystal structure of the mouse innate immunity factor bacterial permeability-increasing family member A1.Acta crystallographica. Section F, Structural biology communications · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Jun L Xue1 Department of Endocrinology, Jingzhou Clinical Medical College, Yangtze University , Jingzhou, People's Republic of China .
Ling Yi2 Department of Central Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University and Beijing Tuberculosis and Thoracic Tumor Research Institute , Beijing, People's Republic of China .
Zhou H Yan2 Department of Central Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University and Beijing Tuberculosis and Thoracic Tumor Research Institute , Beijing, People's Republic of China .
Xin Li3 Hebei Chest Hospital , Shijiazhuang, People's Republic of China .
Xiao J Wang2 Department of Central Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University and Beijing Tuberculosis and Thoracic Tumor Research Institute , Beijing, People's Republic of China .
Pang J Wei2 Department of Central Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University and Beijing Tuberculosis and Thoracic Tumor Research Institute , Beijing, People's Republic of China .
Jiao E Zeng1 Department of Endocrinology, Jingzhou Clinical Medical College, Yangtze University , Jingzhou, People's Republic of China .
Yan L Zhao4 Chinese Center for Disease Control and Prevention , Beijing, People's Republic of China .
Hong T Zhang2 Department of Central Laboratory, Beijing Key Laboratory for Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University and Beijing Tuberculosis and Thoracic Tumor Research Institute , Beijing, People's Republic of China .
Beijing Chest Hospital · CNYangtze University · CNCenter for Disease Control · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SPLUNC1 (Short palate, lung and nasal epithelium clone1) protein is an abundant secretory product of epithelia present throughout the conducting airways. Although its function is still not fully known, most studies have focused on its defensive effect in the infection of human airways and its potential to serve as a molecular marker for lung cancer. In this study, we further evaluated the SPLUNC1 expression in patients with lung disease to explore its role in cancer or tuberculosis at the protein level. We generated a panel of antibodies by using protein from a eukaryotic expression system as the immunogen to mice. It was the panel of SPLUNC1 monoclonal antibodies that allowed us to comparatively determine SPLUNC1 protein in lung cancer and tuberculosis infection by detecting sera and pleural effusion other than airway surface. The results showed that the SPLUNC1 level was not significantly changed either from sera of lung cancer or control. There was a significant increase in pleural effusion from lung cancer when compared to tuberculosis. These results indicate that SPLUNC1 may be a useful marker for tracing lung cancer cells, based on its epithelial origin property in pleural effusion.

Indexed as

AdenocarcinomaAnimalsAntibodies, MonoclonalAntibody SpecificityBiomarkersCarcinoma, Large CellCarcinoma, Squamous CellCase-Control StudiesEnzyme-Linked Immunosorbent AssayFollow-Up StudiesGlycoproteinsHumansHybridomasLung NeoplasmsMicePhosphoproteinsAntibodies, MonoclonalBiomarkersBPIFA1 protein, humanGlycoproteinsPhosphoproteins

Identifiers

PMID26090599
PMCPMC4492706
OpenAlexW1443284156

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.